Patent 7897382 was granted and assigned to Alnylam Pharmaceuticals on March, 2011 by the United States Patent and Trademark Office.
The invention features methods of analyzing the kinetics properties of transfection reactions. Also featured are methods for creating structural promoters which are effectively unregulated by enhancers and repressors. The structural promoters are significantly more active than the native promoter sequences upon which they are based.